DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 08/19/2026 was filed after the mailing date of the non-final on 05/21/2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Status of the Claims
Claims 1-4, 6-10, 14-16, and 18-26 are pending in this application. Claims 5, 11-13, and 17 have been cancelled by applicant. Claims 1-3 and 23-26 are under examination herein. Claims 4, 6-10, 14-16, and 18-22 are withdrawn from consideration, there being no allowable linking claim.
Allowable Subject Matter
Claims 1-2 and 24 are allowed.
Claim Objections
Claim 23 is objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 3 and 25-26 are rejected under 35 U.S.C. 103 as being unpatentable over Chang et al. (US 2009/0318425 A1) (“Chang”).
Regarding claims 3 and 25, Chang discloses their compounds of Formula (I) below (abstract and [0167]), which can be used for the treatment of cancers and cancer pain (see Chang’s claim 68) – reading on the intended use of the instant compounds. Chang specifically discloses their preferred embodiment 10 below, for example, which reads on the instant compounds of Formula (I) when instant ring B is a substituted C6 aryl (phenyl) and ring A is
PNG
media_image1.png
59
76
media_image1.png
Greyscale
or
PNG
media_image2.png
55
68
media_image2.png
Greyscale
(page 45, col. 1).
PNG
media_image3.png
171
447
media_image3.png
Greyscale
(I)
PNG
media_image4.png
267
584
media_image4.png
Greyscale
While Chang doesn’t disclose specific compounds wherein the ring corresponding to instant ring A is
PNG
media_image1.png
59
76
media_image1.png
Greyscale
or
PNG
media_image2.png
55
68
media_image2.png
Greyscale
, Chang teaches particular variations to their ring A (corresponding to instant ring A) can be
PNG
media_image1.png
59
76
media_image1.png
Greyscale
or
PNG
media_image2.png
55
68
media_image2.png
Greyscale
(see [0202] and Chang’s claim 22). Thus, Chang discloses a relatively small genus which overlaps with the claimed subgenus of Formula I.
Therefore, regarding claims 3 and 25, one having ordinary skill in the art would have found the claimed compounds prima facie obvious, since they are generically embraced by Chang’s disclosed formula; In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971). See MPEP 2144.08. The requisite motivation for arriving at the claimed compounds stems from the fact that they fall within the generic class of ASK1 inhibitor compounds disclosed by Chang et al. for the treatment of cancers and cancer pain. Accordingly, one having ordinary skill in the art would have been motivated to prepare any of the compounds embraced by the disclosed generic formula, including those encompassed by the claims.
Furthermore, Applicant is advised, a novel useful compound that is isomeric with the prior art compound is unpatentable unless it possesses some unobvious or unexpected beneficial property not possessed by the prior art compound. In re Norris, 179 F.2d. 970, 84 USPQ 458 (CCPA 1950). Therefore, it would have been obvious to one of ordinary skill to expect similar properties of structurally similar compounds since they are suggestive of one another. It has been held that a compound, which is structurally isomeric with a compound of the prior art, is prima facie obvious absent unexpected results. In re Finely, 81 USPQ 383 (CCPA 1949); 84 USPQ 458 (CCPA 1950).
Regarding claims 3 and 25-26, Chang discloses their compound 6 below wherein the ring corresponding to instant ring B is
PNG
media_image5.png
92
160
media_image5.png
Greyscale
(page 43, col. 2) and when instant ring A is
PNG
media_image6.png
72
78
media_image6.png
Greyscale
. While Chang’s compound 6 doesn’t have a methylated pyrazole (as required by the instant claims); Chang teaches their ring A (corresponding to instant ring A) can be
PNG
media_image7.png
110
181
media_image7.png
Greyscale
(Chang’s claim 37).
PNG
media_image8.png
250
507
media_image8.png
Greyscale
Therefore, regarding claims 3 and 25-26, one having ordinary skill in the art would have found the claimed compounds prima facie obvious, since they are generically embraced by Chang’s disclosed formula and preferred embodiments. The requisite motivation for arriving at the claimed compounds stems from the fact that they fall within the generic class of ASK1 inhibitor compounds disclosed by Chang et al. Accordingly, one having ordinary skill in the art would have been motivated to prepare any of the compounds embraced by the disclosed generic formula, including those encompassed by the claims.
Furthermore, Applicant is advised that H vs. Me is considered an obvious modification in the absence of superior, unexpected results. Note In re Bowers 149 USPQ 570. Note also In re Fauque 121 USPQ 425 in which differences were 2H’s vs 2 methyl groups. Also see MPEP 2144.09.
Response to Arguments
Claims
Claim amendments are acknowledged and have been entered. No new matter has been introduced.
Claim Rejections - 35 USC § 103
In view of claim amendments, 35 USC § 103 rejections over Swinnen et al. have been withdrawn. However, upon further consideration, a new ground of rejections has been raised herein, necessitated by amendments.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JACKSON J HERNANDEZ whose telephone number is (571)272-5382. The examiner can normally be reached Mon - Thurs 7:30 to 5.
Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L. Klinkel can be reached at (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JACKSON J HERNANDEZ/Examiner, Art Unit 1627
/SARAH PIHONAK/Primary Examiner, Art Unit 1627